TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36075249

Group type: EXPERIMENTAL
Intervention: ABX464 100 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: ABX464 50 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: ABX464 25 mg
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 33820822

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg) plus decitabine (10 mg/day, days 1-5) every 3 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Camrelizumab (200 mg) monotherapy
Number of subjects: 61
Study: 33405297

Group type: COMPARATOR
Intervention: 100% Insulin-to-Carbohydrate Ratio (ICR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 140% Insulin-to-Carbohydrate Ratio (ICR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 160% Insulin-to-Carbohydrate Ratio (ICR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 100% ICR to 160% ICR
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Increasing insulin dose (100% to 160% ICR)
Number of subjects: 27
Study: 35982198

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine bolus of 1.5 mg/kg over 5 min followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lidocaine administration
Number of subjects: 58
Study: 32673250

Group type: EXPERIMENTAL
Intervention: Hybrid interactive voice response survey
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Computer-assisted telephone interview
Number of subjects: 1766
Study: 36182236

Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: 12-week open-group behavioural programme
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: 52-week open-group behavioural programme
Number of subjects: 1269

Group type: COMPARATOR
Intervention: 52-week programme vs. brief intervention
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: 52-week programme vs. 12-week programme
Number of subjects: 1269

Group type: COMPARATOR
Intervention: 12-week programme vs. brief intervention
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: 12-week programme
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: 52-week programme
Number of subjects: 1269
Study: 32936055

Group type: EXPERIMENTAL
Intervention: Videoconferencing literacy interventions
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18
Study: 33186492

Group type: COMPARATOR
Intervention: Polypill (40 mg simvastatin, 100 mg atenolol, 25 mg hydrochlorothiazide, 10 mg ramipril)
Number of subjects: 5713

Group type: COMPARATOR
Intervention: Aspirin (75 mg)
Number of subjects: 5713

Group type: COMPARATOR
Intervention: Polypill plus Aspirin
Number of subjects: 5713

Group type: COMPARATOR
Intervention: Polypill
Number of subjects: 5713
Study: 33106446

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg, 20 min before surgery)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Psychological preparation (booklet and explanation by anaesthesia resident)
Number of subjects: 48
Study: 36424542

Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg PO once
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azithromycin 500 mg PO once, followed by Azithromycin 250 mg PO daily for four days
Number of subjects: 0
Study: 33693468

Group type: EXPERIMENTAL
Intervention: Provitamin A carotenoid-biofortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate-fortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Conventional maize (0 µg RE/d)
Number of subjects: 255
Study: 32410922

Group type: EXPERIMENTAL
Intervention: Body Weight (BW)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Lean Body Weight (LBW)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Cardiac Output (CO)
Number of subjects: 327
Study: 35294272

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Blood Glucose Monitoring (BGM) followed by Continuous Glucose Monitoring (CGM)
Number of subjects: 203
Study: 32255565

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting hospital-acquired pressure injuries (HAPIs)
Number of subjects: 2341
Study: 35641112

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 188

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 188
Study: 34105265

Group type: EXPERIMENTAL
Intervention: Aripiprazole orally disintegrating tablets (10 mg) in fasting state
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aripiprazole orally disintegrating tablets (10 mg) in fed state
Number of subjects: 60

Group type: COMPARATOR
Intervention: Test and reference formulations (both fasting and fed conditions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Test and reference formulations
Number of subjects: 60
Study: 35909369

Group type: EXPERIMENTAL
Intervention: Vedolizumab or Adalimumab
Number of subjects: 611
Study: 34936830

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (8 mg)
Number of subjects: 9
Study: 33075170

Group type: EXPERIMENTAL
Intervention: Sublingual wafer (25 mg CBD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sublingual wafer (50 mg CBD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oil solution (50 mg CBD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nabiximols oromucosal spray (20 mg CBD, 21.6 mg THC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sublingual wafer (50 mg CBD, multiple doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sublingual wafer and oil solution
Number of subjects: 12
Study: 32590831

Group type: EXPERIMENTAL
Intervention: Long-axis in-plane approach
Number of subjects: 97

Group type: COMPARATOR
Intervention: Short-axis out-of-plane approach
Number of subjects: 97
Study: 36087572

Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 46
Study: 33030035

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection
Number of subjects: 78

Group type: COMPARATOR
Intervention: Local anesthetic injection (control group)
Number of subjects: 78
Study: 32407460

Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (0.5 mg once daily)
Number of subjects: 4745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4745
Study: 32319740

Group type: EXPERIMENTAL
Intervention: Chronomodulated Irinotecan (morning delivery)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Chronomodulated Irinotecan (afternoon delivery)
Number of subjects: 193
Study: 35526293

Group type: EXPERIMENTAL
Intervention: PragmaCom intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study: 33884972

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sevoflurane-propofol combination
Number of subjects: 31
Study: 35660971

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (EXP2–3A)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (EXP3B–5)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 176
Study: 34991489

Group type: EXPERIMENTAL
Intervention: M-ESD group (using multi-loop traction device)
Number of subjects: 34

Group type: COMPARATOR
Intervention: C-ESD group (conventional ESD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MLTD
Number of subjects: 34
Study: 32035704

Group type: EXPERIMENTAL
Intervention: Surgically managed patients with MRI-verified soft tissue injuries
Number of subjects: 56

Group type: COMPARATOR
Intervention: Surgically managed patients without MRI-verified soft tissue injuries
Number of subjects: 56
Study: 33573895

Group type: EXPERIMENTAL
Intervention: Handwritten rehearsal of core and custom consent items
Number of subjects: 90

Group type: COMPARATOR
Intervention: Audiovisual presentation (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall anxiety levels
Number of subjects: 90
Study: 32294881

Group type: EXPERIMENTAL
Intervention: Food hygiene intervention (food hygiene + handwashing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food hygiene and WASH intervention (food hygiene + handwashing + faeces management + water management)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (food hygiene and WASH intervention)
Number of subjects: 0
Study: 34923257

Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard shoes (control)
Number of subjects: 70
Study: 33068751

Group type: EXPERIMENTAL
Intervention: Active TNS treatment for 4 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham TNS treatment for 4 weeks (control)
Number of subjects: 51
Study: 32576214

Group type: EXPERIMENTAL
Intervention: Additional oversight in the Notice version
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Monitoring and adjusting practices
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Identifying adaptations while maintaining core components
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Conducting initial training
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Regularly sharing lessons learned
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Age ≤ 35 years
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: < 5 years in primary role
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: More prior academic detailing around pain and opioid safety
Number of subjects: 89
Study: 35738968

Group type: EXPERIMENTAL
Intervention: S-268019-b
Number of subjects: 204

Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 204
Study: 34903257

Group type: EXPERIMENTAL
Intervention: Home-based intervention combining psychological treatment for depression and a parenting programme (10 sessions: 4 antenatal and 6 postnatal sessions, plus a booster session at 16 months)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enhanced Standard of Care (ESoC: 2 antenatal and 2 postnatal counselling support and advice telephone calls)
Number of subjects: 528
Study: 35433421

Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with neoadjuvant chemotherapy (neoCT)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (neoCRT)
Number of subjects: 342
Study: 33883758

Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 86

Group type: COMPARATOR
Intervention: Skeletal traction
Number of subjects: 86
Study: 36131595

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33542474

Group type: EXPERIMENTAL
Intervention: Retinal microvascular fractal dimension
Number of subjects: 628
Study: 33142521

Group type: EXPERIMENTAL
Intervention: Phytosterols (25 mg/kg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Antibiotics (200 mg/kg oxytetracycline calcium and 250 mg/kg nosiheptide)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 360
Study: 36484304

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Number of subjects: 302
Study: 33999494

Group type: EXPERIMENTAL
Intervention: Duration of diversion >328 days
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Duration of diversion
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Nasogastric intubation
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 173
Study: 32799042

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 108
Study: 36420938

Group type: EXPERIMENTAL
Intervention: OL-HDF (FxCordiax HDF 800TM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Theranova 500®
Number of subjects: 14

Group type: COMPARATOR
Intervention: Elisio 21HXTM
Number of subjects: 14
Study: 34459426

Group type: EXPERIMENTAL
Intervention: Tele-health CIMT (Tele-AutoCITE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: In-lab CIMT
Number of subjects: 24
Study: 34245292

Group type: EXPERIMENTAL
Intervention: Intradialytic non-immersive virtual reality exercise programme
Number of subjects: 56
Study: 35126309

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum K50 (LPK)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 32543211

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 110
Study: 35596529

Group type: EXPERIMENTAL
Intervention: Intravenous perampanel (12 mg) administered via 30- or 60-minute infusion
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous perampanel (12 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous perampanel
Number of subjects: 48
Study: 34510846

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Semi-Fowler position
Number of subjects: 275

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 275
Study: 35462428

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study: 32088207

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 34972488

Group type: EXPERIMENTAL
Intervention: SHRed Injuries Basketball program (10-minute program with 13 exercises)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Unsupervised SHRed Injuries Basketball program
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Supervised SHRed Injuries Basketball program
Number of subjects: 502

Group type: COMPARATOR
Intervention: Standard-of-practice warm-up (control group)
Number of subjects: 502
Study: 32034876

Group type: EXPERIMENTAL
Intervention: Hands-on organ slicing (experimental group)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Prosection mode (control group)
Number of subjects: 182
Study: 36415902

Group type: EXPERIMENTAL
Intervention: Light exposure stimulus at varying intensities (5 to 5000 lux) for 1 hour before bedtime
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Light exposure stimulus
Number of subjects: 33
Study: 33485088

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound showing presence of a halo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound showing occlusion of the TA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Unilateral pain
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Visual disturbances
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Correlation between duplex findings and biopsy
Number of subjects: 81
Study: 32173214

Group type: EXPERIMENTAL
Intervention: Health education and counseling intervention (3 walking and face-to-face group sessions plus text messages)
Number of subjects: 164
Study: 33389521

Group type: EXPERIMENTAL
Intervention: 6 mg dexamethasone phosphate (DEX-P) administered orally (PO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6 mg betamethasone phosphate (BET-P) administered orally (PO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of betamethasone phosphate and acetate (BET-PA) administered intramuscularly (IM)
Number of subjects: 48
Study: 33181081

Group type: EXPERIMENTAL
Intervention: Febuxostat (80 mg/day, increasing to 120 mg/day if necessary)
Number of subjects: 6128

Group type: COMPARATOR
Intervention: Allopurinol (optimised dose)
Number of subjects: 6128

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6128

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6128
Study: 34119741

Group type: EXPERIMENTAL
Intervention: JianpiQinghua (JQ) granules (34.8 g) plus omeprazole (10 mg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Omeprazole (20 mg)
Number of subjects: 204
Study: 32133684

Group type: EXPERIMENTAL
Intervention: Digital Patient Journey (DPJ) solution
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 66
Study: 35717703

Group type: EXPERIMENTAL
Intervention: This Girl Can campaign (multi-session exposure)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control videos/images depicting idealized women of thin/athletic body types
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control videos highlighting physical activity benefits
Number of subjects: 339
Study: 33445218

Group type: EXPERIMENTAL
Intervention: Endoscopic cyanoacrylate injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration (BRTO)
Number of subjects: 64
Study: 32192350

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 49
Study: 36494649

Group type: EXPERIMENTAL
Intervention: Salad bar intervention in 70 schools (half of the matched pairs)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Pre-portioned fruits and vegetables only in 71 schools (half of the matched pairs)
Number of subjects: 141
Study: 32623646

Group type: EXPERIMENTAL
Intervention: US-guided (USG) knee procedures
Number of subjects: 41

Group type: COMPARATOR
Intervention: Landmark-guided (LMG) knee procedures
Number of subjects: 41
Study: 33032180

Group type: EXPERIMENTAL
Intervention: Prophylactic oral nutritional supplements (ONS) from the beginning of CCRT
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group received nutritional support only when necessary
Number of subjects: 114
Study: 34071293

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10,000 IU daily for 14 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 34980026

Group type: EXPERIMENTAL
Intervention: PHI-101 (Chk2 inhibitor)
Number of subjects: 36
Study: 33837890

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study: 35604694

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33054601

Group type: EXPERIMENTAL
Intervention: Training (10 months)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Detraining (5 months after 10 months training)
Number of subjects: 49
Study: 35041454

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 3025
Study: 34509423

Group type: EXPERIMENTAL
Intervention: Deep-learning model for segmentation of geographic atrophy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Deep-learning model for segmentation of retinal pigment epithelium loss
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Deep-learning model for segmentation of overlying photoreceptor degeneration
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Deep-learning model for segmentation of hypertransmission
Number of subjects: 200

Group type: COMPARATOR
Intervention: Human specialist grading
Number of subjects: 200
Study: 36116545

Group type: EXPERIMENTAL
Intervention: 4 °C saline irrigation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 °C saline irrigation
Number of subjects: 48

Group type: COMPARATOR
Intervention: 25 °C saline irrigation (control)
Number of subjects: 48
Study: 34209617

Group type: EXPERIMENTAL
Intervention: 1500 mg/day of Golden Root Extract (GRE; Rhodiola rosea)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL; gluten‐free cornstarch)
Number of subjects: 10
Study: 32517382

Group type: EXPERIMENTAL
Intervention: Repeated Sprint Ability Test (RSA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yo-Yo Intermittent Recovery Test Level 1 (YYIR1)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1-min LnSDNN:LnRMSSD ratio
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HRVUST LnSDNN:LnRMSSD ratio
Number of subjects: 25
Study: 35912804

Group type: EXPERIMENTAL
Intervention: Nutrition program, physical activity, synbiotic Acidolac, and vitamin D3 for 3 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care (nutrition program and physical activity) for 3 months
Number of subjects: 130
Study: 34328433

Group type: COMPARATOR
Intervention: Group exercise program (delivered online)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Personal exercise program (delivered online)
Number of subjects: 241
Study: 32534728

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia (HTG) prevalence
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Sex- and age-adjusted HTG prevalence
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Triglyceride levels in men
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Triglyceride levels in women
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Association with hypercholesterolemia
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Association with low HDL-C
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Association with hepatic steatosis
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Association with diabetes
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Association with obesity
Number of subjects: 6588
Study: 35083729

Group type: EXPERIMENTAL
Intervention: Probiotic drops containing Limosilactobacillus reuteri (DSM 17938 and ATCC PTA 5289) given as 5 daily drops at bedtime for 12 months.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo drops (identically composed but lacking bacteria) given for 12 months.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Probiotic drops
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 38
Study: 35869984

Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 0

Group type: COMPARATOR
Intervention: eculizumab
Number of subjects: 0
Study: 34890354

Group type: EXPERIMENTAL
Intervention: Pink Journey app (intervention group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96